Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Conclusion: Treatment of RA patients with filgotinib led to the decrease of multiple cytokines involved in various aspects of the inflammatory process. Reductions in IL-6 and IL-1β establish the anti-inflammatory activity of filgotinib. Treatment effects on IL-2, IL-6, IL-7, IL-12 and IFN-γ that play a key role in CD4+ T-cell differentiation and expansion further highlight the anti-inflammatory effects of filgotinib, likely by limiting the promotion of TH1, TH2 and TH17 cells. Finally, effects on innate immunity, through MIP-1β and GM-CSF decrease, were also mediated by filgotinib. Taken together, these data further demonstrate the anti-inflammatory activity of filgotinib in line with its efficacy observed in RA patients.
To cite this abstract in AMA style:Taylor PC, Westhovens R, Meuleners L, Meuleman B, Pan Y, Vyncke V, Van der Aa A, Harrison P, Tasset C, Galien R. The JAK1-Selective Inhibitor Filgotinib Displays an Anti-Inflammatory Biomarker Signature in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-jak1-selective-inhibitor-filgotinib-displays-an-anti-inflammatory-biomarker-signature-in-rheumatoid-arthritis-patients/. Accessed November 28, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-jak1-selective-inhibitor-filgotinib-displays-an-anti-inflammatory-biomarker-signature-in-rheumatoid-arthritis-patients/